Immix Biopharma (IMMX) Gains from Sales and Divestitures (2023 - 2025)
Immix Biopharma's (IMMX) quarterly Gains from Sales and Divestitures came in at $41023.0 in Q1 2025, down 87.96% year-on-year from $340808.0 in Q1 2024, and down 63.19% quarter-over-quarter from $111444.0 in Q4 2024.
Immix Biopharma (IMMX) Gains from Sales and Divestitures (2023 - 2025) Analysis & Trends
Immix Biopharma has disclosed Gains from Sales and Divestitures across 3 years of filings, most recently posting $41023.0 for Q1 2025.
- Gains from Sales and Divestitures for Q1 2025 came in at $41023.0, down 87.96% year-over-year; the trailing twelve-month figure through Mar 2025 was $41023.0 (down 87.96% YoY), and the FY2024 annual result was $111444.0, down 71.07% from the prior year.
- Gains from Sales and Divestitures came in at $41023.0 for Q1 2025 at Immix Biopharma, down from $111444.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $429504.0 in Q3 2023 to a low of $21876.0 in Q1 2023.
- The 3-year median for Gains from Sales and Divestitures is $252287.0 (2024), against an average of $230023.6.
- Across the five-year window, Gains from Sales and Divestitures jumped 1457.91% in 2024 and plunged 87.96% in 2025, its largest moves.
- Immix Biopharma's Gains from Sales and Divestitures stood at $385156.0 in 2023, then slumped by 71.07% to $111444.0 in 2024, then tumbled by 63.19% to $41023.0 in 2025.
- The last three Gains from Sales and Divestitures figures came in at $41023.0 (Q1 2025), $111444.0 (Q4 2024), and $181864.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Immix Biopharma | 467.59 Mn | 467.59 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 41,023.00 |
| Mar 31, 2025 | 41,023.00 |
| Dec 31, 2024 | 111,444.00 |
| Dec 31, 2024 | 111,444.00 |
| Sep 30, 2024 | 181,864.00 |
| Sep 30, 2024 | 181,864.00 |
| Jun 30, 2024 | 252,287.00 |
| Jun 30, 2024 | 252,287.00 |
| Mar 31, 2024 | 340,808.00 |
| Mar 31, 2024 | 340,808.00 |
| Dec 31, 2023 | 385,156.00 |
| Dec 31, 2023 | 385,156.00 |
| Sep 30, 2023 | 429,504.00 |
| Sep 30, 2023 | 429,504.00 |
| Jun 30, 2023 | 306,250.00 |
| Jun 30, 2023 | 306,250.00 |
| Mar 31, 2023 | 21,876.00 |
| Mar 31, 2023 | 21,876.00 |